title: Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking.
abstract: BACKGROUND
  To report acute and late toxicity in prostate cancer patients treated by dose escalated intensity-modulated radiation therapy (IMRT) and organ tracking.
  
  
  METHODS
  From 06/2004 to 12/2005 39 men were treated by 80 Gy IMRT along with organ tracking. Median age was 69 years, risk of recurrence was low 18%, intermediate 21% and high in 61% patients. Hormone therapy (HT) was received by 74% of patients. Toxicity was scored according to the CTC scale version 3.0. Median follow-up (FU) was 29 months.
  
  
  RESULTS
  Acute and maximal late grade 2 gastrointestinal (GI) toxicity was 3% and 8%, late grade 2 GI toxicity dropped to 0% at the end of FU. No acute or late grade 3 GI toxicity was observed. Grade 2 and 3 pre-treatment genitourinary (GU) morbidity (PGUM) was 20% and 5%. Acute and maximal late grade 2 GU toxicity was 56% and 28% and late grade 2 GU toxicity decreased to 15% of patients at the end of FU. Acute and maximal late grade 3 GU toxicity was 8% and 3%, respectively. Decreased late > or = grade 2 GU toxicity free survival was associated with higher age (P = .025), absence of HT (P = .016) and higher PGUM (P < .001).
  
  
  CONCLUSIONS
  GI toxicity rates after IMRT and organ tracking are excellent, GU toxicity rates are strongly related to PGUM.
authors.affiliation: Department of Radiation Oncology with Division of Medical Radiation Physics, University of Bern, Inselspital, Bern, Switzerland, Freiburgstrasse, 3010 Bern, Switzerland. pirus.ghadjar@insel.ch
authors.forename: Pirus
authors.initials: P
authors.lastname: Ghadjar
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Vock
authors.forename: Daniel
authors.initials: D
authors.lastname: Vetterli
authors.forename: Peter
authors.initials: P
authors.lastname: Manser
authors.forename: Roland
authors.initials: R
authors.lastname: Bigler
authors.forename: Jan
authors.initials: J
authors.lastname: Tille
authors.forename: Axel
authors.initials: A
authors.lastname: Madlung
authors.forename: Frank
authors.initials: F
authors.lastname: Behrensmeier
authors.forename: Roberto
authors.initials: R
authors.lastname: Mini
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Aebersold
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000209:etiology; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects*; D012008:Recurrence; D012306:Risk; D013997:Time Factors; D016896:Treatment Outcome